human ERBB2 protein
Medicine & Life Sciences
60%
Drug Therapy
Medicine & Life Sciences
30%
glucose-6-phosphate dehydrogenase A-
Medicine & Life Sciences
30%
Ado-Trastuzumab Emtansine
Medicine & Life Sciences
29%
Neoplasms
Medicine & Life Sciences
24%
Fingolimod Hydrochloride
Medicine & Life Sciences
24%
Glucosephosphate Dehydrogenase Deficiency
Medicine & Life Sciences
24%
Triple Negative Breast Neoplasms
Medicine & Life Sciences
24%
Shen, C. Y. ,
Au, P. C. M. ,
Baek, Y. H. ,
Cheung, C. L. ,
Chung, W. P. ,
Kim, J. H. ,
Kleinman, N. J. ,
Lam, T. C. ,
Liao, T. C. ,
Lin, T. C. ,
Shin, J. Y. ,
Sing, C. W. ,
Wong, I. C. K. &
Lai, E. ,
2022 , (Accepted/In press)
於: BioDrugs. 研究成果: Article › 同行評審
Zoledronic Acid
100%
Denosumab
91%
Pamidronate
76%
Cohort Studies
59%
Retrospective Studies
58%
Chung, W. P. ,
Huang, W. L. ,
Liao, W. A. ,
Hung, C. H. ,
Chiang, C. W. ,
Cheung, C. H. A. &
Su, W. C. ,
2022 12月 ,
於: Scientific reports. 12 ,
1 , 241.
研究成果: Article › 同行評審
Fingolimod Hydrochloride
100%
human ERBB2 protein
88%
Heterografts
18%
Annexin A5
11%
In Situ Nick-End Labeling
10%
Chung, W. P. ,
Yang, H. L. ,
Hsu, Y. T. ,
Hung, C. H. ,
Liu, P. Y. ,
Liu, Y. W. ,
Chan, S. H. &
Tsai, K. L. ,
2022 3月 ,
於: Annals of Physical and Rehabilitation Medicine. 65 ,
2 , 101485.
研究成果: Article › 同行評審
Randomized Controlled Trials
100%
Exercise
96%
Drug Therapy
87%
Heart Ventricles
21%
Echocardiography
20%
Ado-Trastuzumab Emtansine
100%
human ERBB2 protein
37%
Confidence Intervals
29%
taxane
23%
Interstitial Lung Diseases
13%
Chung, W. P. ,
Yang, C. T. ,
Chen, H. Y. ,
Su, C. Y. ,
Su, H. W. &
Ou, H. T. ,
2022 1月 ,
於: Journal of the Formosan Medical Association. 121 ,
1 ,
p. 319-328 10 p. 研究成果: Article › 同行評審
Triple Negative Breast Neoplasms
100%
Survival
45%
Drug Therapy
43%
Therapeutics
13%
taxane
11%